BillionToOne Q3 net income more than triples to $17.39 million

• BillionToOne’s third-quarter 2026 diluted earnings per share more than tripled year-over-year to $0.32.
• Revenue climbed 47% year-over-year to $123 million, driven by higher test volume and average selling prices.
• Northstar Clear, a blood-only MRD test for patients with all solid tumors, will launch commercially December 15, 2026.
• Full-year 2026 revenue guidance rose to $460 million–$470 million, with profitability expected to remain near current levels despite continued investment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Billiontoone Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041605PRIMZONEFULLFEED9870562) on November 04, 2026, and is solely responsible for the information contained therein.